Data in Advanced Colorectal Cancer Show Disease Control Rate of 80% at Target Dose Anti-Tumor Activity Observed Across Multiple Solid Tumors CodeBreaK is the Most Extensive KRAS G12C Clinical Development Program THOUSAND OAKS, Calif., May 29, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the CodeBreaK 100 clinical development program evaluating investigational AMG 510 (proposed INN sotorasib) in heavily pretreated patients with a range of KRAS G12C-mutant solid tumors.These data demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors, including pancreatic, appendiceal and endometrial cancer.